SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CEL-SCI Corporation - CVM

New York, New York--(Newsfile Corp. - July 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether CEL-SCI and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On June 28, 2021, CEL-SCI issued a press release announcing that the Phase 3 study for the Company's Multikine (leukocyte interleukin) immunotherapy candidate missed its primary endpoint for primary (previously untreated) squamous cell carcinoma of the head and neck.

On this news, CEL-SCI's stock price fell $11.39 per share, or 45.41%, to close at $13.69 per share on June 28, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/89446